683 Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

683 Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.4M	Sell	128,100 -13,000	-9%	-$4.42M	2.21%	7
2025 Q4	$56.1M	Buy	141,100 +5,400	+4%	+$2.39M	2.44%	9
2025 Q3	$61.9M	Sell	135,700 -5,600	-4%	-$2.28M	3.23%	7
2025 Q2	$46.1M	Buy	141,300 +90,100	+176%	+$24.9M	3.03%	7
2025 Q1	$13.8M	Sell	51,200 -7,500	-13%	-$1.93M	0.95%	30
2024 Q4	$13.8M	Sell	58,700 -64,600	-52%	-$17M	0.86%	32
2024 Q3	$33.9M	Buy	123,300 +400	+0.3%	+$104K	2.58%	9
2024 Q2	$29.9M	Buy	122,900 +87,100	+243%	+$13.8M	2.26%	10
2024 Q1	$5.35M	Buy	+35,800	New	+$5.97M	0.39%	54
2023 Q4	–	Sell	-10,000	Closed	-$1.77M	–	260
2023 Q3	$1.77M	Buy	+10,000	New	+$1.91M	0.14%	87

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

683 Capital Management's ALNY Position: Q1 2026 in Review

683 Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 455% in Q1 2026, buying an estimated $5.86M and bringing the position to 21,000 shares worth $6.95M. The position accounts for 0.36% of the portfolio, ranked #57.

683 Capital Management first reported a position in ALNY in Q3 2016 and has held it in 26 quarters since. The position peaked at $30.5M in Q1 2019. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

683 Capital Management held 21,000 shares of Alnylam Pharmaceuticals worth $6.95M as of Q1 2026.
683 Capital Management bought 17,218 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.86M.
Alnylam Pharmaceuticals made up 0.36% of 683 Capital Management's portfolio in Q1 2026, its #57 holding.
683 Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 26 quarters since.
683 Capital Management's Alnylam Pharmaceuticals position peaked at $30.5M in Q1 2019.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.